Summit Therapeutics Analyst Price Targets

Summit Therapeutics Inc

SMMTNASDAQ

$14.43

0.271.91%

Últ. Act.: Sep 2, 9:55 AM

Wall Street analyst price targets and consensus rating for Summit Therapeutics (SMMT).

Price Target Range — 11 Quarters

Analyst Consensus — 17 Analysts

3S.Buy

9Buy

5Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$32Upside to Avg. PT+121.4%

Rating Trend — Last 9 Months

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 26, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
Aug 25, 2026	Bernstein	Jeffrey Walch	Upgrade	Underperform→Market Perform	$10→$12
Aug 18, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
Aug 12, 2026	Leerink Partners	Daina Graybosch	Upgrade	Underperform→Market Perform	$12→$13
Jul 24, 2026	Stifel	Dara Azar	PT Cut	Buy	$45→$38
Jul 24, 2026	Guggenheim	Brad Canino	PT Cut	Buy	$40→$38
Jul 23, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
May 22, 2026	Bernstein	Jeffrey Walch	Initiate	Underperform	$8
May 22, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Downgrade	Buy→Neutral	—
May 4, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$30→$23
May 1, 2026	Piper Sandler	Kelsey Goodwin	PT Cut	Neutral	$17→$16
Apr 8, 2026	Stifel	Dara Azar	Initiate	Buy	$45
Mar 16, 2026	Jefferies	Clara Dong	Downgrade	Buy→Hold	$42→$15
Feb 24, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$40→$30
Feb 2, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$40
Jan 30, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$40
Dec 17, 2025	Barclays	Etzer Darout	Upgrade	Underweight→Equal-Weight	$16→$18
Nov 18, 2025	Wolfe Research	Kalpit Patel	Initiate	Peer Perform	—
Oct 22, 2025	Guggenheim	Brad Canino	Maintained	Buy	$40
Oct 21, 2025	Barclays	Etzer Darout	PT Raise	Underweight	$13→$16